Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -139.87% | -125.63% | -136.92% | 511.54% | 186.02% |
| Total Depreciation and Amortization | -13.94% | -16.04% | -14.86% | -15.62% | -17.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 94.94% | 66.87% | 21.19% | -5.74% | -37.44% |
| Change in Net Operating Assets | -700.93% | -1,095.49% | 123.46% | 100.06% | 149.75% |
| Cash from Operations | -172.50% | -160.55% | 438.52% | 329.89% | 518.26% |
| Capital Expenditure | -31.72% | -44.99% | -334.59% | -218.58% | -158.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -26.21% | -38.82% | -317.29% | -218.58% | -158.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.18% | 10.00% | -2.67% | -4.79% | 17.49% |
| Issuance of Common Stock | -23.84% | -26.88% | -23.81% | -0.72% | 42.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -24.35% | -41.76% | -47.88% | -6.87% | 642.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -180.28% | -168.55% | 410.03% | 308.84% | 475.97% |